Business Context and Reporting Period
This Form 8-K Current Report is filed by Teva Pharmaceutical Industries Limited for the reporting period ending September 9, 2026. The filing primarily discloses the pricing and terms of a significant multi-currency senior notes offering executed by the Company's finance subsidiaries.
Key Financial Metrics and Transaction Details
The Company entered into an underwriting agreement to issue Senior Notes with an aggregate principal amount of approximately $4.7 billion (comprising both Euro and USD denominations). The specific tranches are as follows:
- 2033 Euro Notes: €1,000,000,000 principal at 4.250% coupon; priced at 98.756% of principal.
- 2036 Euro Notes: €500,000,000 principal at 4.625% coupon; priced at 98.327% of principal.
- 2032 USD Notes: $1,200,000,000 principal at 5.250% coupon; priced at 98.993% of principal.
- 2034 USD Notes: $1,000,000,000 principal at 5.500% coupon; priced at 98.659% of principal.
- 2037 USD Notes: $1,000,000,000 principal at 5.750% coupon; priced at 98.520% of principal.
The sale of these Securities is expected to close on September 16, 2026. The filing does not provide specific revenue, profit, cash flow, or margin figures for the period, as this is a transactional disclosure rather than a periodic financial report.
Material Changes and Outlook
The primary material change is the expansion of the Company's debt capital structure through the issuance of the new Senior Notes. The offering was registered under the Securities Act of 1933 via a Registration Statement on Form S-3ASR filed on February 7, 2025. The underwriters include major financial institutions such as BNP Paribas, Citigroup, Goldman Sachs, and J.P. Morgan.
The filing does not contain specific management commentary on future operational guidance, risks, or contingencies beyond the standard representations and warranties in the Underwriting Agreement. No unusual items or restatements of prior financial data are mentioned in this text.
Investor Verification Checklist
- Verify the final closing date of the offering (expected September 16, 2026) and the actual net proceeds received after underwriting discounts.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants, redemption rights, and default provisions.
- Confirm the intended use of proceeds from the €1.5 billion Euro Notes and $3.2 billion USD Notes.
- Assess the impact of the new debt load on the Company's leverage ratios and interest coverage, given the coupon rates ranging from 4.250% to 5.750%.
- Check subsequent filings for any changes to the pricing or terms prior to the closing date.